Nintedanib reduces radiation-induced microscopic lung fibrosis but this cannot be monitored by CT imaging: A preclinical study with a high precision image-guided irradiator

Radiotherapy and Oncology

Volumn 124, Issue 3, 2017, Pages 482-487

  De Ruysscher, Dirk ^a,b   Granton, Patrick Vincent ^a   Lieuwes, Natasja Gaby ^a   van Hoof, Stefan ^a   Wollin, Lutz ^c   Weynand, Birgit ^b   Dingemans, Anne Marie ^a   Verhaegen, Frank ^a   Dubois, Ludwig ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Nintedanib; Radiation fibrosis; Radiation pneumonitis; Radiation induced lung damage; Small animal image guided precision irradiation

Indexed keywords

NINTEDANIB; INDOLE DERIVATIVE;

ALVEOLAR WALL THICKNESS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY MEDIA; ARTICLE; ATELECTASIS; CONTROLLED STUDY; DRUG EFFICACY; FIBROSING ALVEOLITIS; HISTOLOGY; IMAGE GUIDED RADIOTHERAPY; IMMUNOHISTOCHEMISTRY; LUNG ALVEOLUS WALL; LUNG EDEMA; LUNG FIBROSIS; LYMPH NODE; LYMPHORETICULAR INFILTRATION; MACROPHAGE; MALE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NON INVASIVE PROCEDURE; NONHUMAN; PERIVASCULAR FIBROSIS; PHENOTYPE; PNEUMONIA; PRECLINICAL STUDY; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; RESPIRATORY TRACT PARAMETERS; RETICULOENDOTHELIAL SYSTEM; ANIMAL; C57BL MOUSE; DEVICES; DIAGNOSTIC IMAGING; DISEASE MODEL; LUNG; RADIATION RESPONSE; X-RAY COMPUTED TOMOGRAPHY;

ANIMALS; DISEASE MODELS, ANIMAL; INDOLES; LUNG; MALE; MICE; MICE, INBRED C57BL; PULMONARY FIBROSIS; RADIATION INJURIES; RADIOTHERAPY, IMAGE-GUIDED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 85026368891     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2017.07.014     Document Type: Article

References (35)

1. Cappuccini, F., Eldh, T., Bruder, D., et al. New insights into the molecular pathology of radiation-induced pneumopathy. Radiother Oncol 101 (2011), 86–92.
2. Vansteenkiste, J., De Ruysscher, D., Eberhardt, W.E., et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24 (2013), vi89–vi98.
3. Appelt, A.L., Vogelius, I.R., Farr, K.P., Khalil, A.A., Bentzen, S.M., Towards individualized dose constraints: adjusting the QUANTEC radiation pneumonitis model for clinical risk factors. Acta Oncol 53 (2014), 605–612.
4. Defraene, G., van Elmpt, W., Crijns, W., Slagmolen, P., De Ruysscher, D., CT characteristics allow identification of patient-specific susceptibility for radiation-induced lung damage. Radiother Oncol 117 (2015), 29–35.
5. Kerns, S.L., West, C.M., Andreassen, C.N., et al. Radiogenomics: the search for genetic predictors of radiotherapy response. Future Oncol 10 (2014), 2391–2406.
6. Reck, M., Kaiser, R., Mellemgaard, A., et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 15 (2014), 143–155.
7. Bonella, F., Stowasser, S., Wollin, L., Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib. Drug Des Devel Ther 9 (2015), 6407–6419.
8. Wollin, L., Wex, E., Pautsch, A., et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J 45 (2015), 1434–1445.
9. Wollin, L., Maillet, I., Quesniaux, V., Holweg, A., Ryffel, B., Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther 349 (2014), 209–220.
10. Ozawa, Y., Abe, T., Omae, M., et al. Impact of preexisting interstitial lung disease on acute, extensive radiation pneumonitis: retrospective analysis of patients with lung cancer. PLoS One, 10, 2015, e0140437.
11. Granton, P.V., Dubois, L., van Elmpt, W., et al. A longitudinal evaluation of partial lung irradiation in mice by using a dedicated image-guided small animal irradiator. Int J Radiat Oncol Biol Phys 90 (2014), 696–704.
12. Brayton, C.F., Treuting, P.M., Ward, J.M., Pathobiology of aging mice and GEM: background strains and experimental design. Vet Pathol 49 (2012), 85–105.
13. Shackelford, C., Long, G., Wolf, J., Okerberg, C., Herbert, R., Qualitative and quantitative analysis of nonneoplastic lesions in toxicology studies. Toxicol Pathol 30 (2002), 93–96.
14. ten Hallers, E.J., Jansen, J.A., Marres, H.A., Rakhorst, G., Verkerke, G.J., Histological assessment of titanium and polypropylene fiber mesh implantation with and without fibrin tissue glue. J Biomed Mater Res A 80 (2007), 372–380.
15. van Hoof, S.J., Granton, P.V., Verhaegen, F., Development and validation of a treatment planning system for small animal radiotherapy: SmART-Plan. Radiother Oncol 109 (2013), 361–366.
16. Grosse, C., Grosse, A., CT findings in diseases associated with pulmonary hypertension: a current review. Radiographics 30 (2010), 1753–1777.
17. Ghobadi, G., van der Veen, S., Bartelds, B., et al. Physiological interaction of heart and lung in thoracic irradiation. Int J Radiat Oncol Biol Phys 84 (2012), e639–e646.
18. van der Veen, S.J., Ghobadi, G., de Boer, R.A., et al. ACE inhibition attenuates radiation-induced cardiopulmonary damage. Radiother Oncol 114 (2015), 96–103.
19. Devine, A., Marignol, L., Potential of amifostine for chemoradiotherapy and radiotherapy-associated toxicity reduction in advanced NSCLC: a meta-analysis. Anticancer Res 36 (2016), 5–12.
20. Kharofa, J., Cohen, E.P., Tomic, R., Xiang, Q., Gore, E., Decreased risk of radiation pneumonitis with incidental concurrent use of angiotensin-converting enzyme inhibitors and thoracic radiation therapy. Int J Radiat Oncol Biol Phys 84 (2012), 238–243.
21. Small, W. Jr., James, J.L., Moore, T.D., et al. Utility of the ACE inhibitor captopril in mitigating radiation-associated pulmonary toxicity in lung cancer: results from NRG oncology RTOG 0123. Am J Clin Oncol, 2016.
22. Li, M., Abdollahi, A., Grone, H.J., Lipson, K.E., Belka, C., Huber, P.E., Late treatment with imatinib mesylate ameliorates radiation-induced lung fibrosis in a mouse model. Radiat Oncol, 4, 2009, 66.
23. Milas, L., Nishiguchi, I., Hunter, N., et al. Radiation protection against early and late effects of ionizing irradiation by the prostaglandin inhibitor indomethacin. Adv Space Res 12 (1992), 265–271.
24. Yahyanejad, S., van Hoof, S.J., Theys, J., et al. An image guided small animal radiation therapy platform (SmART) to monitor glioblastoma progression and therapy response. Radiother Oncol 116 (2015), 467–472.
25. Hallahan, D.E., Geng, L., Shyr, Y., Effects of intercellular adhesion molecule 1 (ICAM-1) null mutation on radiation-induced pulmonary fibrosis and respiratory insufficiency in mice. J Natl Cancer Inst 94 (2002), 733–741.
26. Jackson, I.L., Vujaskovic, Z., Down, J.D., A further comparison of pathologies after thoracic irradiation among different mouse strains: finding the best preclinical model for evaluating therapies directed against radiation-induced lung damage. Radiat Res 175 (2011), 510–518.
27. Prasse, A., Pechkovsky, D.V., Toews, G.B., et al. A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18. Am J Respir Crit Care Med 173 (2006), 781–792.
28. Magnini, D., Montemurro, G., Iovene, B., et al. Idiopathic pulmonary fibrosis: molecular endotypes of fibrosis stratifying existing and emerging therapies. Respiration 93 (2017), 379–395.
29. Formenti, S.C., Demaria, S., Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst 105 (2013), 256–265.
30. Wollin, L., Schuett, J., Ostermann, A., Herrmann, F., The effect of nintedanib on platelet derived growth factor-stimulated contraction of human primary lung fibroblasts. Am J Respir Crit Care Med, 193, 2016, A2384.
31. Wollin, L., Ostermann, A., Brauchle, V., Williams, C., Nintedanib inhibits pro-fibrotic mediators with relevance in connective tissue disease-associated interstitial lung diseases. Am J Respir Crit Care Med, 195, 2017, A2450.
32. Tandon, K., Herrmann, F., Ayaub, E., et al. Nintedanib attenuates the polarization of profibrotic macrophages through the inhibation of thyrosine phosphorylation on Csf1 receptor. Am J Respir Crit Care Med, 195, 2017, A2397.
33. Justet, A., Laurent-Bellue, A., Thabut, G., et al. [18F]FDG PET/CT predicts progression-free survival in patients with idiopathic pulmonary fibrosis. Respir Res, 18, 2017, 74.
34. Maher, T.M., Aerobic glycolysis and the Warburg effect. An unexplored realm in the search for fibrosis therapies?. Am J Respir Crit Care Med 192 (2015), 1407–1409.
35. Groves, A.M., Win, T., Screaton, N.J., et al. Idiopathic pulmonary fibrosis and diffuse parenchymal lung disease: implications from initial experience with 18F-FDG PET/CT. J Nucl Med 50 (2009), 538–545.